Emanuela Merla

1.4k total citations
17 papers, 390 citations indexed

About

Emanuela Merla is a scholar working on Pathology and Forensic Medicine, Neurology and Hematology. According to data from OpenAlex, Emanuela Merla has authored 17 papers receiving a total of 390 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pathology and Forensic Medicine, 10 papers in Neurology and 5 papers in Hematology. Recurrent topics in Emanuela Merla's work include Lymphoma Diagnosis and Treatment (11 papers), CNS Lymphoma Diagnosis and Treatment (10 papers) and Acute Myeloid Leukemia Research (4 papers). Emanuela Merla is often cited by papers focused on Lymphoma Diagnosis and Treatment (11 papers), CNS Lymphoma Diagnosis and Treatment (10 papers) and Acute Myeloid Leukemia Research (4 papers). Emanuela Merla collaborates with scholars based in Italy, Australia and Belarus. Emanuela Merla's co-authors include S Tura, Pier Luigi Zinzani, Filíppo Gherlinzoni, Maurizio Bendandi, Massimo Magagnoli, Marzia Salvucci, Alessandro Gozzetti, Giovanni Frezza, G. Frezza and Giuseppe Visani and has published in prestigious journals such as Blood, Annals of Oncology and Leukemia Research.

In The Last Decade

Emanuela Merla

16 papers receiving 371 citations

Peers

Emanuela Merla
Gene Resnick United States
Daniele Bertoloni Italy
Luciano Guardigni Italy
Sotirios Sachanas Greece
Diana Libster Israel
Serafín Delgado Mexico
Annalisa Gabriele Italy
Geundoo Jang South Korea
R. Tubbs United States
Sabrina Aliberti Italy
Gene Resnick United States
Emanuela Merla
Citations per year, relative to Emanuela Merla Emanuela Merla (= 1×) peers Gene Resnick

Countries citing papers authored by Emanuela Merla

Since Specialization
Citations

This map shows the geographic impact of Emanuela Merla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emanuela Merla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emanuela Merla more than expected).

Fields of papers citing papers by Emanuela Merla

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emanuela Merla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emanuela Merla. The network helps show where Emanuela Merla may publish in the future.

Co-authorship network of co-authors of Emanuela Merla

This figure shows the co-authorship network connecting the top 25 collaborators of Emanuela Merla. A scholar is included among the top collaborators of Emanuela Merla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emanuela Merla. Emanuela Merla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Federico, Vincenzo, Rosella Matera, Emanuela Merla, et al.. (2024). Treosulfan Plus Fludarabine (TTF10) As Preparative Regimen before Haploidentical Trasplant in Elderly Patients with Acute Myeloid Leukemia. Blood. 144(Supplement 1). 7294–7294. 1 indexed citations
2.
3.
4.
Zinzani, Pier Luigi, Cinzia Pellegrini, Emanuela Merla, et al.. (2012). Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study. Hematological Oncology. 31(4). 179–182. 14 indexed citations
5.
Scalzulli, Potito Rosario, Maria Rosa Valvano, Angelo Michele Carella, et al.. (2007). Intermediate Dose Melphalan, Bortezomib, Thalidomide, Dexametasone (MVTD) Conditioning Therapy and ASCT in Relapsed Multiple Myeloma Patients: A Single Center Experience.. Blood. 110(11). 5117–5117. 1 indexed citations
6.
Cascavilla, Nicola, Angelo Michele Carella, Matteo Dell’Olio, et al.. (2007). Gemtuzumab Ozogamicin as Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Patients with Acute Myeloid Leukemia (AML).. Blood. 110(11). 4380–4380.
7.
Cascavilla, Nicola, Angelo Michele Carella, Matteo Dell’Olio, et al.. (2006). Use of Intrathecal Liposomal Cytarabine (DepoCyte) as Treatment of Lymphomatous Meningitis.. Blood. 108(11). 4677–4677. 2 indexed citations
8.
Zinzani, Pier Luigi, Massimo Magagnoli, Giovanni Frezza, et al.. (1999). ABVD and Radiation Therapy as First-Line Treatment in Advanced Hodgkin's Disease. Leukemia & lymphoma. 32(5-6). 553–559. 8 indexed citations
9.
Zinzani, Pier Luigi, Massimo Magagnoli, Filíppo Gherlinzoni, et al.. (1998). To what extent can indolent lymphoma be considered? Results of a long term follow-up study from a single center.. PubMed. 83(6). 502–7. 7 indexed citations
10.
Zinzani, Pier Luigi, Maurizio Bendandi, Massimo Magagnoli, et al.. (1997). Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma. Annals of Oncology. 8(4). 379–383. 41 indexed citations
11.
Zinzani, Pier Luigi, Massimo Magagnoli, Stefano Ascani, et al.. (1997). Nongastrointestinal mucosa-associated lymphoid tissue (MALT) lymphomas: Clinical and therapeutic features of 24 localized patients. Annals of Oncology. 8(9). 883–886. 48 indexed citations
12.
Zinzani, Pier Luigi, Massimo Magagnoli, Maurizio Bendandi, et al.. (1997). Primary intestinal lymphoma: clinical and therapeutic features of 32 patients.. PubMed. 82(3). 305–8. 90 indexed citations
13.
Zinzani, Pier Luigi, Maurizio Bendandi, Giuseppe Visani, et al.. (1996). Adult Lymphoblastic Lymphoma: Clinical Features and Prognostic Factors in 53 Patients. Leukemia & lymphoma. 23(5-6). 577–582. 44 indexed citations
14.
Zinzani, Pier Luigi, Maurizio Bendandi, G. Frezza, et al.. (1996). Primary Mediastinal B-Cell Lymphoma with Sclerosis: Clinical and Therapeutic Evaluation of 22 Patients. Leukemia & lymphoma. 21(3-4). 311–316. 26 indexed citations
15.
Zinzani, Pier Luigi, Maurizio Zompatori, Maurizio Bendandi, et al.. (1996). Monitoring Bulky Mediastinal Disease with Gallium-67, CT-Scan and Magnetic Resonance Imaging in Hodgkin's Disease and High-Grade Non-Hodgkin's Lymphoma. Leukemia & lymphoma. 22(1-2). 131–135. 26 indexed citations
16.
Zinzani, Pier Luigi, Maurizio Bendandi, Filíppo Gherlinzoni, et al.. (1996). FLU-ID (fludarabine and idarubicin) regimen as salvage therapy in pretreated low-grade non-Hodgkin's lymphoma.. PubMed. 81(2). 168–71. 20 indexed citations
17.
Pileri, S., Elena Sabattini, Simonetta Poggi, et al.. (1994). Bone-marrow biopsy in hairy cell leukaemia (HCL) patients. Histological and immunohistological analysis of 46 cases treated with different therapies.. PubMed. 14 Suppl 1. 67–71. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gene Resnick Breakdown of academic impact, for papers by Daniele Bertoloni Breakdown of academic impact, for papers by Luciano Guardigni Breakdown of academic impact, for papers by Sotirios Sachanas Breakdown of academic impact, for papers by Diana Libster Breakdown of academic impact, for papers by Serafín Delgado Breakdown of academic impact, for papers by Annalisa Gabriele Breakdown of academic impact, for papers by Geundoo Jang Breakdown of academic impact, for papers by R. Tubbs Breakdown of academic impact, for papers by Sabrina Aliberti
Rankless by CCL
2026